Evidence map›Paper›PMID 40527777›Full record

ArticleMedicine2025

Computed tomography radiomics prediction of survival in hepatocellular carcinoma and is associated with ADH1A expression of the retinol metabolism pathway.

Ting-Yu Yu, Ze-Juan Zhan, Qi Lin

Abstract read
In one paragraph

Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ting-Yu YuRadiology Department, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.ORCID 0009-0006-8897-3406
Ze-Juan Zhan
Qi Lin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to construct a prognostic model of hepatocellular carcinoma (HCC) patients based on radiomics features and to explore the corresponding mechanisms. Patients' data and computed tomography images were collected from the Cancer Genome Atlas and the Cancer Imaging Archive. The radiomics features were extracted and screened via 3D Slicer and the Least Absolute Shrinkage and Selection Operator regression analysis for radiomics model construction, with rad score (RS) calculated. The net reclassification index, integrated discrimination improvement, receiver operating characteristic curve, and decision curve analysis were utilized to evaluate the prediction efficiency of the model. Restricted Cubic Splines and Kaplan-Meier were used to analyze the association between RS and overall survival (OS). The differentially expressed genes between the high- and low-RS groups were collected for enrichment analyses to screen the key pathways and core genes. Based on 4 key features associated with OS, a model was constructed: RS = 0.626* Gray Level Nonuniformity Normalized + 0.063*Dependence Nonuniformity Normalized - 0.253* Long Run Low Gray Level Emphasis - 35.93* Contrast. The radiomics model had superior performance in predicting OS, and high RS was associated with poor OS (P < .05). Moreover, RS may influence HCC prognosis through ADH1A regulation of the retinol metabolism pathway. The prognostic model based on radiomics features has good predictive performance in HCC patients. The RS model may promote HCC progression through ADH1A regulation of the retinol metabolism pathway.

Indexed as

Alcohol DehydrogenaseCarcinoma, HepatocellularLiver NeoplasmsTomography, X-Ray ComputedVitamin AAgedFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisRadiomicsROC CurveAlcohol DehydrogenaseVitamin Acomputed tomographyhepatocellular carcinomaradiomics modelretinol metabolism pathway

Identifiers

PMID40527777
PMCPMC12173319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.